Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CI
stocks logo

CI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
69.30B
+5.51%
7.896
+18.92%
67.13B
+2.48%
7.296
+8.25%
71.25B
+6.06%
7.378
+2.47%
Estimates Revision
The market is revising Upward the revenue expectations for The Cigna Group (CI) for FY2025, with the revenue forecasts being adjusted by 2.76% over the past three months. During the same period, the stock price has changed by -11.71%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.14%
In Past 3 Month
Stock Price
Go Down
down Image
-11.71%
In Past 3 Month
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 268.420
sliders
Low
294.00
Averages
337.60
High
378.00
Current: 268.420
sliders
Low
294.00
Averages
337.60
High
378.00
Guggenheim
Buy
maintain
$309 -> $318
2025-12-02
New
Reason
Guggenheim
Price Target
$309 -> $318
2025-12-02
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Cigna to $318 from $309 and keeps a Buy rating on the shares.
BofA
initiated
2025-11-19
Reason
BofA
Price Target
2025-11-19
initiated
Reason
BofA analysts added Cigna to the firm's "US 1 List," which represents a collection of its best investment ideas.
Bernstein
Lance Wilkes
Market Perform
downgrade
$346 -> $294
2025-11-12
Reason
Bernstein
Lance Wilkes
Price Target
$346 -> $294
2025-11-12
downgrade
Market Perform
Reason
Bernstein analyst Lance Wilkes lowered the firm's price target on Cigna to $294 from $346 and keeps a Market Perform rating on the shares following quarterly results. The firm is also adjusting its EPS model to reflect pressure in the PBM margin, with 2026 Evernorth earnings expected down 4% due to Pharmacy Benefit Services subsegment margin declining by an estimated 17%, offset by growth in the specialty segment and Cigna Healthcare.
Goldman Sachs
Scott Fidel
Buy
downgrade
$370 -> $330
2025-11-05
Reason
Goldman Sachs
Scott Fidel
Price Target
$370 -> $330
2025-11-05
downgrade
Buy
Reason
Goldman Sachs analyst Scott Fidel lowered the firm's price target on Cigna to $330 from $370 and keeps a Buy rating on the shares.
Wells Fargo
Equal Weight
downgrade
$354 -> $300
2025-11-05
Reason
Wells Fargo
Price Target
$354 -> $300
2025-11-05
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Cigna to $300 from $354 and keeps an Equal Weight rating on the shares. The firm's 2026 / 2027 / 2028 EPS estimates also decrease 10% / 13% / 14% following PBM pressures in 2026. While Wells is sympathetic to arguments that PBM earnings may be overly discounted, low visibility and lack of catalysts keeps the firm on the sidelines.
TD Cowen
Charles Rhyee
Buy
downgrade
$387 -> $333
2025-11-04
Reason
TD Cowen
Charles Rhyee
Price Target
$387 -> $333
2025-11-04
downgrade
Buy
Reason
TD Cowen analyst Charles Rhyee lowered the firm's price target on Cigna to $333 from $387 and keeps a Buy rating on the shares. The firm updated its estimatesfollowing its Q3 results where it introduced its 2026 framework which calls for adj. EPS growth, EHS seeing a slight decline in adj. pre-tax inc. and CI HC growing at the high end of its LT target growth of 7-10%.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cigna Group (CI.N) is 8.81, compared to its 5-year average forward P/E of 10.88. For a more detailed relative valuation and DCF analysis to assess Cigna Group 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
10.88
Current PE
8.81
Overvalued PE
11.98
Undervalued PE
9.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.89
Undervalued EV/EBITDA
8.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.41
Current PS
0.00
Overvalued PS
0.47
Undervalued PS
0.34
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CI News & Events

Events Timeline

(ET)
2025-11-25
06:20:32
Speaker Johnson cautions that House Republicans oppose ACA subsidies, according to WSJ.
select
link
2025-11-24 (ET)
2025-11-24
14:11:55
White House Delays Healthcare Proposal Following Backlash, Reports MS Now
select
link
2025-11-24
06:47:07
White House anticipated to announce continuation of Obamacare subsidies, according to Politico.
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
12-04SeekingAlpha
Report: Republican Healthcare Plan to Feature Reforms for Pharmacy Benefit Managers

  • Republican Health Care Overhaul: A Republican plan to reform health care will focus on reducing the influence of pharmacy benefit managers (PBMs) to help control drug costs, with details to be discussed in a meeting led by House Speaker Mike Johnson.

  • Countering Subsidy Pressure: As Democrats push to extend enhanced ACA health insurance subsidies to 2026, Republicans aim to present their own bill and are advised to emphasize drug price reductions to counter potential backlash regarding subsidy cuts.

  • Key Pharmacy Benefit Managers: The three major PBMs involved in the discussion are UnitedHealth Group's OptumRx, Cigna's Express Scripts, and CVS Health's Caremark.

  • Public Sentiment on ACA Coverage: A poll indicates that 25% of individuals may drop their ACA insurance coverage if enhanced subsidies are not extended, highlighting the potential impact of subsidy changes on health insurance enrollment.

[object Object]
Preview
8.0
12-04SeekingAlpha
Survey reveals 25% may forgo ACA insurance if extended subsidies are not continued.

  • Impact of Subsidy Expiration: A new Kaiser Family Foundation poll indicates that many individuals using Affordable Care Act exchanges would likely drop their coverage if enhanced premium subsidies are not extended through 2026.

  • Potential Premium Increases: An analysis suggests that ACA marketplace premiums could more than double without the extension of enhanced tax credits, leading to 25% of enrollees potentially going uninsured.

  • Financial Strain on Households: Approximately 60% of enrollees reported they could not manage a $300 annual increase in premiums without significant financial strain, with 20% unable to afford a $1,000 increase.

  • Consequences of Rising Costs: If healthcare costs rise by $1,000 in 2026, two-thirds of enrollees would likely reduce spending on daily needs, while over half might seek additional employment or incur debt.

[object Object]
Preview
7.0
12-03Globenewswire
Cigna Under Investigation for Securities Violations by Schall Law Firm
  • Investigation Launched: The Schall Law Firm is investigating Cigna for potential violations of securities laws, focusing on whether the company issued false or misleading statements, indicating significant legal risks that could impact stock price and market trust.
  • Investor Rights Protection: The firm encourages shareholders who suffered losses to participate in the investigation, highlighting a commitment to investor rights that may prompt increased shareholder attention and potential lawsuits, intensifying legal pressure on the company.
  • Legal Expertise: Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, showcasing its expertise in this area, which may attract more investors seeking legal support and increase Cigna's legal burdens.
  • Potential Consequences: Should the investigation confirm wrongdoing by Cigna, the company could face fines and reputational damage, which would adversely affect its long-term financial performance and market position.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cigna Group (CI) stock price today?

The current price of CI is 268.42 USD — it has decreased -0.7 % in the last trading day.

arrow icon

What is Cigna Group (CI)'s business?

The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.

arrow icon

What is the price predicton of CI Stock?

Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cigna Group (CI)'s revenue for the last quarter?

Cigna Group revenue for the last quarter amounts to 69.75B USD, increased 9.50 % YoY.

arrow icon

What is Cigna Group (CI)'s earnings per share (EPS) for the last quarter?

Cigna Group. EPS for the last quarter amounts to 7.02 USD, increased 166.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cigna Group (CI)'s fundamentals?

The market is revising Upward the revenue expectations for The Cigna Group (CI) for FY2025, with the revenue forecasts being adjusted by 2.76% over the past three months. During the same period, the stock price has changed by -11.71%.
arrow icon

How many employees does Cigna Group (CI). have?

Cigna Group (CI) has 73500 emplpoyees as of December 05 2025.

arrow icon

What is Cigna Group (CI) market cap?

Today CI has the market capitalization of 71.70B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free